These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21223735)

  • 1. [Investigation of chromosome 1 aberrations in patients with multiple myeloma using cIg-FISH method and its significance].
    Yang RF; Li CM; Qiu HR; Lu H; Wu HX; Xu JR; Li JY; Chen LJ
    Zhonghua Xue Ye Xue Za Zhi; 2010 Dec; 31(12):804-8. PubMed ID: 21223735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Investigation of 1q21 amplification in patients with multiple myeloma using I-FISH and cIg-FISH].
    Yang RF; Li CM; Qiu HR; Lu H; Wu HX; Xu JR; Zhang P; Li JY; Chen LJ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Dec; 28(6):686-9. PubMed ID: 22161106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
    Deng P; Zhou YL; Wei YL; Li P; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and biological characteristics multiple myeloma with 1q21 amplification].
    Zhong S; Li C; Yi S; Qiu L
    Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(8):615-9. PubMed ID: 26932854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
    Mohan M; Gong Z; Ashby TC; Al Hadidi S; Thanendrarajan S; Schinke C; Alapat D; Shaughnessy JD; Zhan F; van Rhee F; Sawyer JR; Tian E; Zangari M
    Cancer; 2023 Aug; 129(16):2491-2498. PubMed ID: 37282609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
    Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma.
    Gao X; Li C; Zhang R; Yang R; Qu X; Qiu H; Xu J; Lu H; Li J; Chen L
    Med Oncol; 2012 Sep; 29(3):2200-6. PubMed ID: 21611837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
    Grzasko N; Hus M; Chocholska S; Pluta A; Hajek R; Dmoszynska A
    Leuk Lymphoma; 2012 Dec; 53(12):2500-3. PubMed ID: 22497640
    [No Abstract]   [Full Text] [Related]  

  • 9. [Detection of chromosomal aberrations in multiple myeloma with fluorescence in situ hybridization].
    Cao P; Chen F; Cheng Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 37(10):983-9. PubMed ID: 23117450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
    Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of 1q21 Gain in Multiple Myeloma.
    Chen D; Zhou D; Xu J; Zhou R; Ouyang J; Chen B
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e159-e164. PubMed ID: 30685183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.
    Kastritis E; Migkou M; Dalampira D; Gavriatopoulou M; Fotiou D; Roussou M; Kanellias N; Ntanasis-Stathopoulos I; Malandrakis P; Theodorakakou F; Sevastoudi A; Eleutherakis-Papaiakovou E; Triantafyllou T; Terpos E; Katodritou E; Dimopoulos MA
    Am J Hematol; 2022 Sep; 97(9):1142-1149. PubMed ID: 35731917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population.
    Yu W; Guo R; Qu X; Qiu H; Li J; Zhang R; Chen L
    Onco Targets Ther; 2016; 9():295-302. PubMed ID: 26834489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
    Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
    Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of CD138 Immunomagnetic Sorting Myeloma Cells Combined with Fluorescence in Situ Hybridization for Detecting Cytogenetic Abnormalities of Multiple Myeloma].
    Gao L; Liu Q; Shi Y; Dang H; He Q; Wang Z; Feng L; Li Y; Wang XY; Li N; Song WJ; Wang YL; Kong S; Lu J; Huang XJ; Lai YY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):807-812. PubMed ID: 28641640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications.
    Bahmanyar M; Qi X; Chang H
    Leuk Res; 2013 Dec; 37(12):1726-8. PubMed ID: 24169086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Investigation of the molecular changes in patients with multiple myeloma by fluorescence in situ hybridization].
    Yang RF; Li CM; Chen LJ; Qiu HR; Yang H; Liu P; Xu JR; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):567-70. PubMed ID: 20931539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
    J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.